Alexion
Cheshire, United States · Biotechnology, Health Care, Medical
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medici
Key facts
- Headquarters
- Cheshire, United States
- Employees
- 1,001
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- alexion.com
- Company page
Recent activity at Alexion
- : Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years.
- : Pharmaceutical giant Alexion partners with DHL to use HVO fuel in deliveries
- : Alexion, Astrazeneca Rare Disease, Completes Acquisition Of Logicbio® Therapeutics
- : Alexion, Astrazeneca Rare Disease To Acquire Logicbio® Therapeutics To Accelerate Growth In Genomic Medicine
Employee benefit plans
Alexion files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Jun 2027.
Alexion in the news
- Culture Drives Employee Engagement, Supports Business Growth - Fierce Biotech (Jun 15, 2021)
- AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseases - Fierce Pharma (Jul 21, 2021)
- AstraZeneca concludes Alexion acquisition for $39bn - Pharmaceutical Technology (Jul 22, 2021)
- What You Need to Know About Working at Alexion Pharmaceuticals - BioSpace (Jan 25, 2021)
- Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies - AstraZeneca (Jul 28, 2023)
- AstraZeneca CEO defends 'fantastic' Alexion buyout in face of $753M hit from dropped drug - Fierce Biotech (Feb 06, 2025)
- Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter - Business Wire (Jul 29, 2026)
- AstraZeneca receives US clearance of proposed acquisition of Alexion - AstraZeneca (Apr 16, 2021)
Companies similar to Alexion
- Glaukos Corporation · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Vectura Group Limited · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Ryvu Therapeutics · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- Aquestive Therapeutics, Inc. · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
- InnoCare Pharma · Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
About Alexion: questions and answers
What does Alexion do?
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medici
Where is Alexion headquartered?
Alexion is headquartered in Cheshire, United States.
How many employees does Alexion have?
Alexion has about 1,001 employees.
What is the latest news on Alexion?
On Oct 29, 2026, Wolves Foundation and Alexion extend partnership to support Wolves Disability FC and Wolves Wishes for three more years.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy